| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Alinidine HBr targets the pacemaker current (I_f) in sinoatrial node cells, which is responsible for the diastolic depolarization that initiates heartbeats. By reducing the slope of diastolic depolarization, it slows the heart rate without affecting other cardiac functions.
|
|---|---|
| ln Vitro |
In vitro, Alinidine HBr reduces the diastolic depolarization slope of sinoatrial tissue and Purkinje fibers. It is a specific bradycardic agent with anti-ischemic and antiarrhythmic effects.
|
| ln Vivo |
In vivo, Alinidine HBr is a specific bradycardic agent that slows heart rate. It has anti-ischemic and antiarrhythmic effects. The compound has been studied for its potential in treating cardiac conditions where heart rate reduction is beneficial.
|
| Enzyme Assay |
Alinidine HBr's bradycardic activity can be characterized using electrophysiological assays on sinoatrial tissue or Purkinje fibers. The compound's effects on the diastolic depolarization slope and heart rate can be measured.
|
| Cell Assay |
In vitro cell experiments with Alinidine HBr involve treating sinoatrial node cells or Purkinje fibers with the compound and measuring electrophysiological parameters. The compound's effects on pacemaker currents and action potentials are assessed.
|
| Animal Protocol |
In vivo animal studies with Alinidine HBr have been conducted using animal models to study its bradycardic, anti-ischemic, and antiarrhythmic effects. The compound is typically administered via injection. Detailed protocols are available in the cardiovascular pharmacology literature.
|
| ADME/Pharmacokinetics |
Alinidine HBr has a molecular weight of 351.07 and a molecular formula of C₁₂H₁₄BrCl₂N₃. The compound is stored at 2-8°C, away from moisture. It has a purity of ≥95%.
|
| Toxicity/Toxicokinetics |
Alinidine HBr is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices.
|
| Additional Infomation |
Alinidine HBr (St-567 hydrobromide) is a specific bradycardic agent. It reduces the diastolic depolarization slope of sinoatrial tissue and Purkinje fibers. It has anti-ischemic and antiarrhythmic effects. It has a CAS number of 71306-36-0.
|
| Molecular Formula |
C12H13N3CL2.HBR
|
|---|---|
| Molecular Weight |
351.06966
|
| Exact Mass |
348.975
|
| CAS # |
71306-36-0
|
| PubChem CID |
134052
|
| Appearance |
White to light yellow solid powder
|
| Boiling Point |
360.2ºC at 760 mmHg
|
| Flash Point |
171.7ºC
|
| LogP |
3.667
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
296
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Br.ClC1C=CC=C(Cl)C=1N(CC=C)C1=NCCN1
|
| InChi Key |
JLFOQBZGELKSOT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H13Cl2N3.BrH/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14;/h2-5H,1,6-8H2,(H,15,16);1H
|
| Chemical Name |
N-(2,6-dichlorophenyl)-N-prop-2-enyl-4,5-dihydro-1H-imidazol-2-amine;hydrobromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~284.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8484 mL | 14.2422 mL | 28.4843 mL | |
| 5 mM | 0.5697 mL | 2.8484 mL | 5.6969 mL | |
| 10 mM | 0.2848 mL | 1.4242 mL | 2.8484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
